234 related articles for article (PubMed ID: 25791528)
1. A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.
Hjorth S; Karlsson C; Jucaite A; Varnäs K; Wählby Hamrén U; Johnström P; Gulyás B; Donohue SR; Pike VW; Halldin C; Farde L
Neuropharmacology; 2016 Feb; 101():519-30. PubMed ID: 25791528
[TBL] [Abstract][Full Text] [Related]
2. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo.
Varga B; Kassai F; Szabó G; Kovács P; Fischer J; Gyertyán I
Pharmacol Biochem Behav; 2017 Aug; 159():24-35. PubMed ID: 28666894
[TBL] [Abstract][Full Text] [Related]
4. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
5. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Addy C; Wright H; Van Laere K; Gantz I; Erondu N; Musser BJ; Lu K; Yuan J; Sanabria-Bohórquez SM; Stoch A; Stevens C; Fong TM; De Lepeleire I; Cilissen C; Cote J; Rosko K; Gendrano IN; Nguyen AM; Gumbiner B; Rothenberg P; de Hoon J; Bormans G; Depré M; Eng WS; Ravussin E; Klein S; Blundell J; Herman GA; Burns HD; Hargreaves RJ; Wagner J; Gottesdiener K; Amatruda JM; Heymsfield SB
Cell Metab; 2008 Jan; 7(1):68-78. PubMed ID: 18177726
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of (11)C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors.
Tsujikawa T; Zoghbi SS; Hong J; Donohue SR; Jenko KJ; Gladding RL; Halldin C; Pike VW; Innis RB; Fujita M
Neuroimage; 2014 Jan; 84():733-41. PubMed ID: 24076222
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.
Fong TM; Heymsfield SB
Int J Obes (Lond); 2009 Sep; 33(9):947-55. PubMed ID: 19597516
[TBL] [Abstract][Full Text] [Related]
8. Apparent CB
Grim TW; Morales AJ; Thomas BF; Wiley JL; Endres GW; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2017 Jul; 362(1):210-218. PubMed ID: 28442584
[TBL] [Abstract][Full Text] [Related]
9. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
10. PET imaging studies in rhesus monkey with the cannabinoid-1 (CB1) receptor ligand [11C]CB-119.
Hamill TG; Lin LS; Hagmann W; Liu P; Jewell J; Sanabria S; Eng W; Ryan C; Fong TM; Connolly B; Vanko A; Hargreaves R; Goulet MT; Burns HD
Mol Imaging Biol; 2009; 11(4):246-52. PubMed ID: 19130142
[TBL] [Abstract][Full Text] [Related]
11. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
Nguyen T; Thomas BF; Zhang Y
Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
[TBL] [Abstract][Full Text] [Related]
12. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
Burns HD; Van Laere K; Sanabria-Bohórquez S; Hamill TG; Bormans G; Eng WS; Gibson R; Ryan C; Connolly B; Patel S; Krause S; Vanko A; Van Hecken A; Dupont P; De Lepeleire I; Rothenberg P; Stoch SA; Cote J; Hagmann WK; Jewell JP; Lin LS; Liu P; Goulet MT; Gottesdiener K; Wagner JA; de Hoon J; Mortelmans L; Fong TM; Hargreaves RJ
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9800-5. PubMed ID: 17535893
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
14. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
15. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
Chen B; Hu N
Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
Janero DR; Lindsley L; Vemuri VK; Makriyannis A
Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861
[TBL] [Abstract][Full Text] [Related]
17. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
18. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.
Soler-Cedeno O; Xi ZX
Cells; 2022 Oct; 11(20):. PubMed ID: 36291128
[TBL] [Abstract][Full Text] [Related]
19. [
Takkinen JS; López-Picón FR; Kirjavainen AK; Pihlaja R; Snellman A; Ishizu T; Löyttyniemi E; Solin O; Rinne JO; Haaparanta-Solin M
Neurobiol Aging; 2018 Sep; 69():199-208. PubMed ID: 29909177
[TBL] [Abstract][Full Text] [Related]
20. Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia.
Santos-Molina L; Herrerias A; Zawatsky CN; Gunduz-Cinar O; Cinar R; Iyer MR; Wood CM; Lin Y; Gao B; Kunos G; Godlewski G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
